


CLAIMS

1. Association comprising a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent.
2. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is a compound of formula (I) :



wherein :

- X represents an oxygen or sulphur atom, or a group CH_2 or CH^{R^2} (wherein R^2 together with R^2 forms an additional bond),
- R^1 and R^2 , which may be the same or different, each represent a hydrogen atom, a linear or branched $(\text{C}_1\text{-C}_6)$ alkyl group, an aryl group, an aryl- $(\text{C}_1\text{-C}_6)$ alkyl group in which the alkyl moiety is linear or branched, an aryloxy group, an aryl- $(\text{C}_1\text{-C}_6)$ alkyloxy group in which the alkyl moiety is linear or branched, a linear or branched $(\text{C}_1\text{-C}_6)$ alkoxy group, a hydroxy group, an amino group, a linear or branched $(\text{C}_1\text{-C}_6)$ alkylamino group or a di- $(\text{C}_1\text{-C}_6)$ alkylamino group in which the alkyl moieties are linear or branched,
or R^1 and R^2 together form an oxo, thioxo or imino group,
it also being possible for R^2 together with R^2 to form an additional bond,
- A represents a $(\text{C}_1\text{-C}_6)$ alkylene chain in which one CH_2 group may be replaced by a hetero atom selected from oxygen and sulphur or by a group NR_a (wherein R_a

represents a hydrogen atom or a linear or branched (C₁-C₆)alkyl group), or by a phenylene or naphthylene group,

- R³ and R⁴, which may be the same or different, each represent a hydrogen or halogen atom or a group R, OR or NRR' (wherein R and R', which may be the same or different, each represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group, a linear or branched (C₂-C₆)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, an aryl group, an aryl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, an aryl-(C₂-C₆)alkenyl group in which the alkenyl moiety is linear or branched, an aryl-(C₂-C₆)alkynyl group in which the alkynyl moiety is linear or branched, a heteroaryl group, a heteroaryl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, a heteroaryl-(C₂-C₆)alkenyl group in which the alkenyl moiety is linear or branched, a heteroaryl-(C₂-C₆)alkynyl group in which the alkynyl moiety is linear or branched, a (C₃-C₈)cycloalkyl group, a (C₃-C₈)cycloalkyl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, or a linear or branched (C₁-C₆)polyhaloalkyl group),
or R³ and R⁴, together with the carbon atoms carrying them, when they are carried by two adjacent carbon atoms, form a ring that has 5 or 6 ring members and that may contain a hetero atom selected from oxygen, sulphur and nitrogen,


- R⁵ and R⁶, which may be the same or different, may have any of the meanings of R given hereinbefore,

- D represents:

a benzene nucleus, in which case X cannot represent a group $\begin{array}{c} \text{R}'^2 \\ | \\ \text{CH} \end{array}$ as defined hereinbefore,
or D represents a pyridine, pyrazine, pyrimidine or pyridazine nucleus,

- B represents a linear or branched (C₁-C₆)alkyl group or a linear or branched (C₂-C₆)-alkenyl group, those groups being substituted :

♦ by a group of formula (II) :



wherein :

- R⁷ represents a group $\text{---}\overset{\text{Z}}{\underset{||}{\text{C}}}\text{---OR}$, $\text{---}\overset{\text{Z}}{\underset{||}{\text{C}}}\text{---NRR'}$, $\text{---N(R)}\overset{\text{Z}}{\underset{||}{\text{C}}}\text{---R'}$

or $\text{---N(R)}\overset{\text{Z}}{\underset{||}{\text{C}}}\text{---OR'}$,


wherein Z represents an oxygen or sulphur atom, and R and R', which may be the same or different, may have any of the meanings given hereinbefore,

- and R⁸ represents an aryl group, an arylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, a heteroaryl group, a heteroarylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, CN, tetrazole, ---OR , ---NRR' ,

$\text{---N(R)}\overset{\text{Z}}{\underset{||}{\text{C}}}\text{---R'}$ or $\text{---N(R)}\overset{\text{Z}}{\underset{||}{\text{C}}}\text{---OR'}$,

wherein Z is as defined hereinbefore, and R and R', which may be the same or different, may have any of the meanings given hereinbefore,

♦ or by a group R⁹, wherein R⁹ represents a CN, tetrazole,



wherein Z is as defined hereinbefore, and R and R', which may be the same or different, may have any of the meanings given hereinbefore, n represents 0, 1, 2, 3, 4, 5 or 6, and R¹⁰ and R¹¹, which may be the same or different, each represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group, it being understood that R¹⁰ and R¹¹ cannot simultaneously represent a hydrogen atom,

or B represents a group of formula (II) or a group R⁹ as defined hereinbefore,

it being understood that :

- * the oxime R⁶-C(=N-OR⁵)- can be of Z or E configuration,
- * aryl means a phenyl, naphthyl or biphenyl group, it being possible for those groups to be partially hydrogenated,
- * heteroaryl means any mono- or bi-cyclic aromatic group containing 5 to 10 members, which may be partially hydrogenated in one of the rings in the case of bicyclic heteroaryls and which contains 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur,

it being possible for the aryl and heteroaryl groups thereby defined to be substituted by from 1 to 3 groups selected from linear or branched (C₁-C₆)alkyl, linear or branched (C₁-C₆)polyhaloalkyl, linear or branched (C₁-C₆)alkoxy, hydroxy, carboxy, formyl, NR_bR_c (wherein R_b and R_c, which may be the same or different, each represent a hydrogen atom, a linear or branched (C₁-C₆)alkyl group, an aryl group or a heteroaryl group), ester, amido, nitro, cyano, and halogen atoms,

an enantiomer or diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base.

3. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid, an enantiomer or diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base.

4. Association according to claim 1, wherein the antioxidant agent is coenzyme Q₁₀.

5. Association according to claim 1, wherein the antioxidant agent is vitamin E.

6. Association according to claim 1, which is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)-(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid and coenzyme Q₁₀.

5 7. Association according to claim 1, which is 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)-(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid and vitamin E.

8. Pharmaceutical compositions comprising as active ingredient a compound favouring the lipid and carbohydrate metabolisms in association with an antioxidant agent according
10 to one of claims 1 to 7, on their own or in combination with one or more pharmaceutically acceptable excipients.

9. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of obesity.

10 10. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

11. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.

20 12. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.

13. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.
- 5 14. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.
- 10 15. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.
16. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.